NDA/BLA filedoutcome: unknownconf 0.70

reproxalap — NDA/BLA filed

$ALDX · Aldeyra Therapeutics, Inc. · dry eye disease

Event date

November 1, 2024

582 days ago

Sponsor runway

38 mo

$65.0M liquid

Evidence

“In November 2024, the FDA accepted the reproxalap NDA for filing and set a Prescription Drug User Fee Act date of April 2, 2025.”

Source: 8-K filed 2026-03-17View on EDGAR ↗0001193125-26-109511

Ticker	Drug	Date	Outcome
$ALDX	reproxalap	2025-07-17	unknown
$ALDX	reproxalap	2023-02-07	unknown
$ALDX	reproxalap	2023-02-01	unknown

2 insiders · 0 buys · 2 sells

Sell

2024-08-12

Machatha Stephen

Chief Development Officer

16,041 @ $4.74$76K

Sell

2024-08-12

Greenberg Bruce

See Remarks

10,834 @ $4.74$51K

Date	Insider	Action	Shares	Price	Value
2024-08-12	Machatha StephenChief Development Officer	Sell	16,041	$4.74	$76K
2024-08-12	Greenberg BruceSee Remarks	Sell	10,834	$4.74	$51K